Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers.

The drug is an antibody that targets two complementary pathways that drive inflammatory diseases by neutralizing thymic stromal lymphopoietin and depleting mast cells, the company said.

The phase 1a study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses and multiple ascending doses of CDX-622 in up to 56 healthy participants, the company said.